Actively Recruiting
Methamphetamine and Troriluzole
Led by William Stoops · Updated on 2025-12-23
40
Participants Needed
1
Research Sites
183 weeks
Total Duration
On this page
Sponsors
W
William Stoops
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This will be a human laboratory study evaluating the influence of troriluzole treatment on the effects of methamphetamine. Supported by and included in the Helping to End Addiction Long-term® (HEAL) Initiative.
CONDITIONS
Official Title
Methamphetamine and Troriluzole
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to speak and read English
- Not seeking treatment for drug use at the time of the study
- Male or female aged between 18 and 55 years
- Recent methamphetamine use confirmed by positive urine test and DSM-5 diagnosis of methamphetamine use disorder
- Medically and psychiatrically healthy except for methamphetamine use disorder (and opioid use disorder if applicable) as judged by study physicians
- Normal ECG results as read by a cardiologist
- Females must use effective birth control and not be pregnant or breastfeeding
- No known contraindications or allergies to troriluzole
- For those with co-morbid opioid use disorder, recent opioid use confirmed by positive urine test and DSM-5 diagnosis with physiological dependence (unless proven otherwise by clinical opioid withdrawal scale and urine test)
You will not qualify if you...
- Unable to speak or read English
- Currently seeking treatment for drug use
- Under 18 years or over 55 years of age
- No recent methamphetamine use or no DSM-5 diagnosis of methamphetamine use disorder
- Medically or psychiatrically unhealthy as judged by study physicians
- ECG results outside normal limits as read by a cardiologist
- Females not using effective birth control or who are pregnant or breastfeeding
- Blood pressure over 140/90 mmHg on two consecutive screening visits
- Body mass index less than 18 or greater than 30; weight under 50 kg
- Taking any prescribed medication for a chronic condition
- Laboratory chemistry values more than three times normal at screening or during admission
- History of serious physical disease or diagnosis of certain disorders (including current hepatic disease except asymptomatic HCV, seizure history, diabetes, asthma, CNS tumors)
- Current or recent psychiatric disorders including suicidal ideation that would interfere with participation, except methamphetamine use disorder or tobacco use disorder (and opioid use disorder where applicable)
- Contraindications or allergies to troriluzole
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Psychopharmacology of Addiction Laboratory
Lexington, Kentucky, United States, 40507
Actively Recruiting
Research Team
W
William W Stoops, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here